Results 41 to 50 of about 8,219 (198)

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

RMD Open
Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine kinase inhibitor ...
Joan T Merrill, Yoshiya Tanaka, Amit Saxena, Xiaofeng Zeng, Martin Aringer, David D’Cruz, Kristin M D’Silva, Ling Cheng, Thao T Doan, Karim R Masri   +9 more
doaj   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Uncovering the Therapeutic Target and Molecular Mechanism of Upadacitinib on Sjogren’s Syndrome

Biomedical Engineering and Computational Biology
Objective: Upadacitinib, a selective Janus associated kinase 1 (JAK-1) inhibitor, can be prescribed particularly for the clinical treatment with Crohn’s disease or rheumatoid arthritis.
Youguo Yang, Yuan Liu, Xiaofen Li, Yongping Zeng, Weiqian He, Juan Zhou   +5 more
doaj   +1 more source

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

JAMA Dermatol
Importance Alopecia areata (AA) is a chronic, systemic immune-mediated disease characterized by nonscarring hair loss.
Mostaghimi A, Gooderham MJ, Lynde C, Sinclair R, King B, Hordinsky M, Rudnicka L, Guttman-Yassky E, Serrao R, Ohyama M, Zhang X, Magnolo N, Kwon O, Oddi C, Meerwein S, Soliman AM, Bu X, Duan C, Wu T, Teixeira HD, Lazar A, Passeron T.   +21 more
europepmc   +2 more sources

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

Arthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson, A. Jerrod Anzalone, Kenneth G. Saag, Rahima Begum, AKM F. Rahman, Namrata Singh, Kaleb Michaud, Jasvinder A. Singh, Rena C. Patel, Maria I. Danila, on behalf of the National Clinical Cohort Collaborative Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew M. Southerland, Andrew T. Girvin, Anita Walden, Anjali Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, G. Caleb Alexander, Carolyn T. Bramante, Cavin Ward‐Caviness, Charisse Madlock‐Brown, Christine Suver, Christopher G. Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Donald E. Brown, Eilis Boudreau, Elaine L. Hill, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M. Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold P. Lehmann, Heidi Spratt, Hemalkumar B. Mehta, J. W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Yasmine Islam, Jin Ge, Joel Gagnier, Johanna J. Loomba, John B. Buse, Jomol Mathew, Joni L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Cato, Kimberly Murray, Kristin Kostka, Lavance Northington, Lee Pyles, Lesley Cottrell, Lili M. Portilla, Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Matvey B. Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple‐O'Connor, Michael G. Kurilla, Michele Morris, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis, Penny Wung Burgoon, Philip R. O. Payne, Randeep Jawa, Rebecca Erwin‐Cohen, Rena C. Patel, Richard A. Moffitt, Richard L. Zhu, Rishikesan Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep K. Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steven G. Johnson, Tellen D. Bennett, Tiffany J. Callahan, Umit Topaloglu, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang   +127 more
wiley   +1 more source

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397).
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg   +5 more
doaj   +1 more source

Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis

Children
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-
Perseus V. Patel, Martina Rigmaiden, Alka Goyal, Rachel Bensen, Dorsey Bass, Jonathan Moses, Michael J. Rosen, Ruben J. Colman   +7 more
doaj   +1 more source

REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY) [PDF]

Arquivos de Gastroenterologia
Background: Extraintestinal manifestations (EIMs) significantly impact patients with inflammatory bowel disease (IBD). Janus kinase inhibitors (JAKi) are emerging as a potential treatment.
Viviana PARRA-IZQUIERDO, Oscar ARDILA, Juan Ricardo MÁRQUEZ, Javier RIVEROS, Álvaro Andrés GÓMEZ-VENEGAS, Carlos Andrés MEDRANO-ALMANZA, Manuel BALLESTEROS, Jonathan BARRETO-PÉREZ, Juan Sebastian FRIAS-ORDOÑEZ   +8 more
doaj   +1 more source

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Drugs in Context, 2020
Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which ...
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, Branimir Anić, Matija Tomšič, Vadim Mazurov, Marija Maksimovic, Orsolya Nagy, Jerzy Świerkot, Tzvetanka Petranova, Tiina Veldi, Asta Baranauskaitė, Catalin Codreanu, Daina Andersone, Roy Fleischmann   +14 more
doaj   +1 more source

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Dermatology and Therapy, 2023
Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD ...
Norito Katoh, Masanori Ikeda, Yukihiro Ohya, Hiroyuki Murota, Xiaofei Hu, John Liu, Hayato Niiyama, Takuya Sasaki, Eliza M. Raymundo, Hidehisa Saeki   +9 more
doaj   +1 more source